Section one: Contracting authority/entity
one.1) Name and addresses
THE UNIVERSITY OF BIRMINGHAM
Edgbaston
BIRMINGHAM
B152TT
Contact
Kseniya Samsonik
Country
United Kingdom
NUTS code
UKG31 - Birmingham
Companies House
RC000645
Internet address(es)
Main address
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Education
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Cytek Aurora spectral cytometer
Reference number
SC12413/24
two.1.2) Main CPV code
- 38434510 - Cytometers
two.1.3) Type of contract
Supplies
two.1.4) Short description
The Clinical Immunology Service (CIS) provides a comprehensive Clinical Immunology diagnostics service to the West Midlands, regional services in lymphoma/leukaemia diagnosis and national services for neuro-immunology and myeloma testing. Being situated within the University of Birmingham (UoB), the CIS also provides central trials analysis for a number of national and local research studies and has a strong track record in immunodiagnostic development. The CIS is the anchor tenant for the Precision Health Technologies Accelerator (PHTA) Home - PHTA Ltd, hosted within the Birmingham Health Innovation Campus (BHIC) Birmingham Health Innovation Campus - Birmingham Health Partners. This ambitious new development will leverage the existing Birmingham Health Partners ecosystem to drive innovation and economic growth.
The CIS has built a nationally leading reputation based on our foundations of quality and delivery and has the expertise, reputation, and networks to progress towards being a global leader in diagnostic development, translation and testing. This supports UoB's ambition to become a global top 50 University and contributes towards the success of the PHTA and BHIC.
To ensure the CIS not only remains able to deliver and maintain current business and workload, but also to ensure it can sustain delivery during the move to the PHTA and deliver the anticipated growth in the future, we need to continually update our equipment and methods to ensure improved efficiency, quality and capabilities.
The CIS is a UKAS ISO15189 accredited laboratory offering comprehensive blood cancer, autoimmunity, neuroimmunology, immunodeficiency and allergy diagnostic services to local and national NHS services. Additionally, the CIS hosts the Midlands Integrated Reporting for Haemato-oncology (MIRHO), a blood cancer diagnostic service, providing blood cancer flow cytometry to the whole of West Midlands; this is an area of ensured increased growth as new therapies are commenced and survival improves for blood cancer patients.
To support the growth and development of this service we need to update our flow cytometry platforms and methods. We therefore intend to purchase a Cytek Aurora spectral cytometer.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £311,004.45
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKG31 - Birmingham
two.2.4) Description of the procurement
The Clinical Immunology Service (CIS) provides a comprehensive Clinical Immunology diagnostics service to the West Midlands, regional services in lymphoma/leukaemia diagnosis and national services for neuro-immunology and myeloma testing. Being situated within the University of Birmingham (UoB), the CIS also provides central trials analysis for a number of national and local research studies and has a strong track record in immunodiagnostic development. The CIS is the anchor tenant for the Precision Health Technologies Accelerator (PHTA) Home - PHTA Ltd, hosted within the Birmingham Health Innovation Campus (BHIC) Birmingham Health Innovation Campus - Birmingham Health Partners. This ambitious new development will leverage the existing Birmingham Health Partners ecosystem to drive innovation and economic growth.
The CIS has built a nationally leading reputation based on our foundations of quality and delivery and has the expertise, reputation, and networks to progress towards being a global leader in diagnostic development, translation and testing. This supports UoB's ambition to become a global top 50 University and contributes towards the success of the PHTA and BHIC.
To ensure the CIS not only remains able to deliver and maintain current business and workload, but also to ensure it can sustain delivery during the move to the PHTA and deliver the anticipated growth in the future, we need to continually update our equipment and methods to ensure improved efficiency, quality and capabilities.
The CIS is a UKAS ISO15189 accredited laboratory offering comprehensive blood cancer, autoimmunity, neuroimmunology, immunodeficiency and allergy diagnostic services to local and national NHS services. Additionally, the CIS hosts the Midlands Integrated Reporting for Haemato-oncology (MIRHO), a blood cancer diagnostic service, providing blood cancer flow cytometry to the whole of West Midlands; this is an area of ensured increased growth as new therapies are commenced and survival improves for blood cancer patients.
To support the growth and development of this service we need to update our flow cytometry platforms and methods. We therefore intend to purchase a Cytek Aurora spectral cytometer.
two.2.11) Information about options
Options: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Negotiated without a prior call for competition
- The works, supplies or services can be provided only by a particular economic operator for the following reason:
- procurement aiming at the creation or acquisition of a unique work of art or artistic performance
Explanation:
• Matching component conformity, configuration, instrument settings, acquisition software and IVDR antibody panels (including disease specific panels, e.g. AML) with the Cytek Northern Lights IVD instrument that we are already evaluating in CIS. To the best of our knowledge these are the only available IVD spectral cytometer/validated IVDR antibody panels on the market. This will allow rapid development of new panels for routine immunophenotyping in our clinical diagnostic laboratory with minimal additional training.
• 60+ detection channels for fluorochromes across a broad range of wavelengths, even when peak emission wavelengths show high degrees of overlap. For example, we would like to simultaneously use Pacific Blue, BV421, SuperBright 436 and BV480 in a single tube panel. To our knowledge, this is only feasible with the 5 laser Aurora instrument.
• Antibody reagent options for pre-built multicolour panels (>20 colours) that have been optimized with the instrument. To our knowledge, these are only available for Cytek instruments.
• Characterizing small particles such as extracellular vesicles, with resolution down to 70nm.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
Section five. Award of contract/concession
A contract/lot is awarded: Yes
five.2) Award of contract/concession
five.2.1) Date of conclusion of the contract
15 March 2024
five.2.2) Information about tenders
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor/concessionaire
Cytek Biosciences B.V
Amsterdam
Country
Netherlands
NUTS code
- NL - Netherlands
Cytek Biosciences B.five
74997823
The contractor/concessionaire is an SME
Yes
five.2.4) Information on value of contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession: £311,004.45
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
University of Birmingham
Edgbaston
Country
United Kingdom